GLP-1 medications are a hot topic right now. Drugs like Novo Nordisk’s (NVO) Ozempic and Eli Lilly’s (LLY) Mounjaro are not only transforming individuals’ weight loss and overall health… they’re also presenting significant economic opportunities.

On today’s episode of the SteadyTrade Podcast, Tim Bohen and Matt McCall explore the revolutionary impact of these medications.
Unlike traditional weight-loss methods – which can be challenging due to people’s busy lifestyles – GLP-1 medications lower the barriers to achieving a healthier weight and offer a more accessible and effective solution. This boosts the user’s physical health and productivity.

The economic impact of these drugs has been immense.

According to Goldman Sachs, we can expect to see a significant boost to the economy – not just through sales but via enhanced productivity. It’s a self-fulfilling cycle.

As a result, the market potential for these drugs is massive. Drug manufacturers like Novo Nordisk and Eli Lilly will see substantial growth. In fact, Novo has already become the largest company in European as a result.

But these two companies are far from the only investment opportunities in the GLP-1 medication space…

Smaller players like Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are worth keeping an eye on. In fact, Viking’s rise from its penny-stock beginning illustrates the potential for high returns in this sector.

We also talk about the importance of investing in supply-chain businesses like McKesson (MCK) and Cencora (COR). These firms play a crucial role in the distribution of these medications and provide another avenue to capitalize on their growth.

There are also secondary opportunities to explore – like the increased demand for protein among GLP-1 medication users.

There’s no question that these drugs offer a promising solution to the obesity epidemic and present significant economic benefits through increased productivity and market growth. With a wealth of investment potential in pharmaceutical giants, supply-chain companies, and protein supplement producers, the impact of GLP-1 medications will be felt across a variety of sectors.

This makes it an exciting area to watch for both health enthusiasts and investors.

If you’re either of those – or just want to hear our take on the topic – click here to watch the latest episode of the SteadyTrade Podcast now.

Here’s to the future,

Tim Bohen
Lead Trainer, StockToTrade

Matt McCall
Editor, Market Insights